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occurred in 57.1% of mortality cases, followed by sepsis/septicemia (39.3%), coagu-
lopathies (23.8%), renal failure (19.4%) wasting syndrome/weight loss (18.4%), liver
disease (16.2%) heart failure (9.7%), lymphoma (6.6%), metastatic cancer (3.3%),
pulmonary circulation disorders (2.9%), and solid tumors (2.8%). Regression analy-
ses found that increased mortality and charges were associated with each afore-
mentioned comorbidity except wasting syndromes/weight loss. Significant
(p0.05) odds ratios were observed for inpatient mortality ranging from 1.17 (renal
failure) to 8.06 (sepsis/septicemia) and exponentiated beta-coefficients for charges
ranging from 1.03 (liver disease) to 1.33 (sepsis/septicemia). Various cancers were
associated with substantially worse outcomes. CONCLUSIONS: An increased un-
derstanding of severe comorbidities inHIV/AIDS is of continued importancewithin
hospital settings. Sepsis/septicemia and cancer is particularly associated with in-
creased inpatient mortality and charges.
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OBJECTIVES: Systematically review all randomized trials evaluating licensed rota-
virus vaccines for efficacy and safety on diarrhoea, hospital admission, death and
serious adverse events.METHODS: Electronic searches strategies were performed
until October 2011. Trial eligibility, data extraction and quality assessment were
performed independently by two reviewers. Dichotomous data were pooled using
the risk ratio (RR) and 95% CI. GRADE was used to evaluate evidence quality.
RESULTS: Forty-three RCTs including 190,551 participants were identified; 31 trials
assessed RV1, and 12 RV5. In children  1 year, RV1 (RR0.20, 95%CI0.11 to 0.35; 7
trials, 35,004 participants) and RV5 (RR0.23, 95%CI 0.08 to 0.71; 3 trials, 6953 par-
ticipants) are highly efficacious against severe rotavirus diarrhoea cases and/or
rotavirus diarrhea requiring hospitalization. For all-cause diarrhea, RV1 reduces
severe cases by 42% (RR0.58, 95% CI 0.40 - 0.84; 8291 participants), and RV5 by 72%
(RR0.28, 95%CI 0.16 - 0.48). Both vaccines were also efficacious during the second
year of life (RV1: RR0.16, 95%CI 0.12 - 0.21; 8 trials, 32,854 participants; RV5:
RR0.44, 95%CI 0.22 - 0.88; 4 trials, 9783 participants). For all-cause diarrhoea, RV1
reduces severe cases by 51% (RR0.49, 95%CI 0.40 - 0.60; 2 trials, 6269 participants).
Both vaccines had no impact on mortality, but serious adverse events following
vaccination, including intussusception, were not more common than following
placebo. CONCLUSIONS: RV1 and RV5 vaccines are efficacious and relatively safe.
These data support the WHO’s global vaccine recommendation. Potential reduced
vaccine efficacy in low income countries needs to be addressed. Ongoing safety
monitoring should be continued in countries that have introduced rotavirus vac-
cination.
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WITH VANCOMYCIN (VAN) MINIMUM INHIBITORY CONCENTRATION (MIC)  2
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OBJECTIVES: MRSA-B is associated with high morbidity and cost. Guidelines rec-
ommend alternative treatment when VAN MICs are 2. DAP effectiveness in
MRSA-B patients (pts)with elevatedVANMICs is an important real-world question.
This analysis evaluates outcomes relevant to pts and institutions including clinical
success, DAP-related length of stay (LOS), and infection-related readmission.
METHODS: All pts with MRSA-B were identified in CORE 2010, a retrospective,
multicenter, observational registry of staphylococcal bacteremia pts with VAN
MIC2 mg/L per local lab. Investigators assessed pt outcome (cured, improved,
failed, nonevaluable) at the end or at last contact of DAP therapy. Pt characteristics
and outcomes are based on the efficacy population. All pts were included in the
safety analysis. RESULTS: A total of 158 pts with MRSA-B were identified; 142 had
initial VANMIC2 and were evaluable for outcome: 47%male, 40%65 years, 27%
CrCl 30mL/min, 21% on dialysis, 22% treated in the ICU. Frequent concurrent
infections included skin and skin structure (12%), endocarditis (9%), bone/joint
(8%). Median (min,max) DAP dose and duration were 6 mg/kg (4,11) and 13.5 days
(2,62), respectively. 80% (114/142) received prior antibiotics; (88% of which was
VAN). Success occurred in 89% overall, with no difference between first (89% [25/
28]) and second-line (89% [101/114]) DAP treatment. Time to clinical response
ranged from 1-27 days (median2). Median (min,max) DAP-related LOS was 9 days
(2,44). 21 pts (15%) were evaluated in the ER within 60 days of completing DAP
therapy. Infection-related readmission occurred in 10 pts (7%). 7 pts experienced 9
AEs possibly related to DAP; 5 pts discontinued DAP due to AE. Overall mortality
rate was 12%; 4 pts died within 7 days. CONCLUSIONS: This evaluation of real-
world effectiveness demonstrates that DAP may be a useful agent for MRSA-B
isolates with a VAN MIC2. Additional comparative effectiveness and resource
utilization studies are warranted.
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OBJECTIVES: The objective was to evaluate the efficacy and safety of the combina-
tion TDF/FTCEFV compared to the available treatment combinations in Mexico.
METHODS: We conducted a systematic review using the Cochrane guidelines of
randomized clinical trials in PUBMED,EMBASE, LILACS ANDARTEMISA to compare
TDF/FTCEFV, ABC/3TCEFV, ZDV/3TCEFV, LPV/rTDF/FTC and LPV/rABC/
3TC in naïve adult patients with HIV-1 infection. Themain outcome variables were
RNA HIV-1 copies less than 50/mm3 at 48 and 96 weeks, and grade 2-4 adverse
effects at 48 effects. We used a random model effects for the pooled analysis.
RESULTS:We included 6 articles, 4 at 48 weeks and 2 at 96 weeks. The arms were
grouped by the tree elements of HAART. The combination TDF/FTCEFV was the
most frequently used (3 studies). At 48 and 96 weeks the pooled probabilities to
have 50 RNA copies/ml for TDF/FTCEFVwere 0.771 (CI95% 0.711 – 0.821; n681)
and 0.670 (CI95% 0.607 – 0.727; n232); ZDV/3TCEFV 0.704 (CI95% 0.643 – 0.758;
n243) and 0.610(CI95% 0.546 – 0.671; n231); LPV/rABC/3TC 0.680 (CI95% 0.629 –
0.727; n343) and 0.600(CI95% 0.527 – 0.631; n343); ABC/3TCEFV 0.677 (CI95%
0.509 – 0.809; n437); and LPV/rTDF/FTC 0.670 (CI95% 0.619 – 0.718; n345) and
0.580(CI95% 0.527 – 0.631; n345) respectively. The adverse events rates (hypersen-
sitivity and diarrhea) at 48 weeks were for TDF/FTCEFV 0.005 (CI95% 0.001 – 0.036)
and 0.050 (CI 95% 0.017-0.136) respectively, TDF/FTCEFV show fewer adverse
events than compared to the other treatment regimens (LPV/rTDF/FTC, ABC/
3TCEFV and LPV/rABC/3TC ). At 48 weeks the discontinuation rate for EFV 
ZDV/3TCwas 0.91,( n254) and for LPV/r TDF/FTC 0.041 (n170). CONCLUSIONS:
The combination TDF/FTCEFV is themost studied combination and it is clinically
effective at 48 and 96 weeks, with good safety profile.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment.METHODS:We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2011. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
itywas evaluated as secondary endpoint. Aggregated datawere further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2011, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 andRG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2011-2012. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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OBJECTIVES: To assess the clinical and economic burden of the human immuno-
deficiency virus (HIV) in the US veteran population. METHODS: A retrospective
study including patients diagnosed with HIV between October 1, 2005 and Septem-
ber 30, 2010 was conducted using the Veterans Health Affairs Medical SAS Data-
sets. Health care resource utilization and costs were assessed in the 12-month
follow-up period. Patients’ demographic, clinical and discharge statuseswere com-
pared using Chi-square testing and standardized differences. Student t-tests were
used for the means of continuous variables. Mortality and survival rates were
calculated using the Kaplan and Meier method and the PROC LIFETEST procedure.
RESULTS:Among all study patients diagnosedwith HIV (n29,388), mortality rates
in the 12-month follow-up period were 15.79% (n4,635), and 5.15% for patients
under age 40, 16.25% for patients age 40 to 65, and 30.01% for patients age 65 and
over. The most commonly prescribed medications were emtricitabine/tenofovir
(2.39%), efavirenz (2.34%), sulfamethoxazole/trimethopri (1.88%), lamivudine/zid-
ovudine (1.81%), lopinavir/ritonavir (1.76%), and atazanavir (1.68%). Themost com-
monly performed laboratory tests were for sodium (3.38%), potassium (3.27%), cre-
atinine (3.25%), chloride (3.25%), glucose quant (3.18%), and carbon dioxide content
(2.94%). For patients with HIV, the average numbers of inpatient (0.48), emergency
room (ER) (0.82), physician office (35.31) and outpatient visits (35.56) were calcu-
lated per patient, separately. The percentages of inpatient (24.62%), ER (35.01%),
physician office (99.90%) and outpatient visits (99.93%) were also computed, which
led to the following costs for inpatient ($7,828), ER ($329), physician office ($14,080)
and outpatient visits ($14,450). CONCLUSIONS: This study found that emtricit-
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abine/tenofovir and efavirenz are the most frequently prescribed drugs after diag-
nosis of HIV. More research, however, is required to better understand adverse
events and side effects.
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OBJECTIVES: Healthy People 2020 (HP2020) emphasized the use of community ser-
vices for prevention and treatment of infectious diseases. Pharmacists are in a
unique position to helpwith this goal. This study comparednational immunization
rates to immunization rates of Hispanic patients receiving clinical pharmacist in-
terventions in a community health center (CHC). METHODS: El Paso CHC Latino
patients who were referred to a clinical pharmacist for diabetes and met immuni-
zation criteria between January 1, 2010 to December 31, 2010 were included. The
pharmacist documented whether or not the patient met criteria for Hepatitis A
(HepA), Hepatitis B (HepB), Tetanus-diphtheria-acellular pertussis (Tdap), Pneumo-
cocal, Zoster and Influenza vaccines. If criteria were met and patient consented,
the vaccine(s) were administered. Vaccination rates were calculated by dividing
the number of patients vaccinated by the number of eligible patients. Study immu-
nization rates (SIRs) were comparedwith the latest available (2009) national overall
(OIRs) and the Hispanic immunization (HIRs) rates. RESULTS: For included patients
(N336), HepA SIR was 32.7%, which was higher than both the OIR (9.8%) and HIR
(8.5%). The Zoster SIR (10.1%)was similar to the OIR (10.0%), but higher than theHIR
(4.8%). The Pneumococal SIRs (46.2%: 19-64 years; 65 years: 39.4%) were higher
than HIR in both age groups (12.1%, 40.4%, respectively). It was only higher, how-
ever, in the overall group aged 19-64 years (17.5%), but not in the 65 age group
(60.6%). The influenza SIR was 27.1%, which was higher than the HIR (22.0%), but
lower than the OIR (33.6%). The SIR for HepB (14.6%) and Tdap (42.0%) were lower
than both national rates (HIR:41.8%, 36.7%; and OIR:50.8%, 48.7%, respectively).
CONCLUSIONS: Pharmacist’s immunization rates among Latino patients were
higher when compared to Hispanic national rates for HepA, Zoster, and Pneumo-
cocal and influenza. Community pharmacists can play an instrumental role in
reducing infectious diseases health disparities.
INFECTION – Cost Studies
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OBJECTIVES: Ceftaroline fosamil (CPT, TEFLARO
®
) is a new, broad-spectrum, bac-
tericidal cephalosporin approved in the US for the treatment of community-ac-
quired bacterial pneumonia (CABP). In two randomized controlled CABP trials
(NCT00621504, NCT00509106), clinical cure rates in the modified intent-to-treat
(MITT) efficacy population were 82.6% for CPT and 76.6% for ceftriaxone. Response
rates at Day 4 (MITT population, N141) were 69.6% and 58.3% for CPT and ceftri-
axone. The objective was to assess the budgetary impact of adding CPT to a US
hospital formulary. METHODS: A three-year hospital budget impact model was
constructed to evaluate patients hospitalized with CABP requiring intravenous (IV)
antimicrobial therapy and having PORT risk class scores of III or IV. Patients were
randomized to receive CPT 600mg IV q12h or 1g ceftriaxone IV q24h for 5–7 days.
Clinical cure rates were assumed to be similar to those from CPT phase 3 CABP
trials. Patients failing initial treatment were assumed to be treated successfully
with second-line antibiotic therapy. Length of stay and total cost per hospital day
(by success or failure with initial treatment) were estimated based on a large data-
base from over 100 US hospitals. Other model inputs included: annual number of
CABP admissions; projected annual case growth rate; proportion of CABP target
population initially treated with ceftriaxone; expected proportion of CABP target
population to be treated with CPT; drug cost; cost of antibiotic administration; cost
of second-line antibiotic therapy for patients failing initial therapy. A sensitivity
analysis using 95% confidence limits of clinical cure rates from phase 3 trials pro-
vided varying estimates. RESULTS: Estimated total cost for treating a CABP patient
with CPT is $1102 lower ($18,925 vs. $20,027) than treating a similar patient with
ceftriaxone (sensitivity analysis range: -$6 to -$2,223). CONCLUSIONS: Model esti-
mates indicate adding ceftaroline to formulary does not negatively impact a hos-
pital CABP budget.
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OBJECTIVES: Daptomycin is a cyclic lipopeptide antibiotic that has been commer-
cially available in Europe since 2006. Daptomycin has rapid bactericidal activity
against MRSA and is indicated for gram-positive infections including complicated
skin and skin structure infections (cSSSI), right-sided infective endocarditis and
Staphylococcus aureus bacteremia (BSI). This study aims to quantify the budgetary
impact of utilizing Daptomycin for suspected gram-positive cSSSI and BSI in
Germany.METHODS: A budget impact model was developed to compare the total
direct costs of utilizing vancomycin, linezolid, daptomycin, and “other antibiotics”
as a single category. A decision tree was constructed on the basis of clinical guide-
lines and validated by clinicians. Clinical data and laboratory utilization and cost
data were derived from a comprehensive review of over 40 publications. Antibiotic
utilization and net drug costs were derived using syndicated data from Arlington
Medical Resources (AMR). RESULTS: On average, the total direct costs (drug acqui-
sition, lab monitoring, and hospital) of treating a cSSSI patient with the following
agents were: vancomycin €2598 (4%, 12% and 84%), linezolid €2742 (37%, 5%, and
58%), daptomycin €3,171 (30%, 7%, and 63%), and other antibiotics €1835 (2%, 10%,
and 88%). For BSI patients, total direct costs were: vancomycin €2359 (5%, 13% and
82%), linezolid €3951 (37%, 5%, and 58%), daptomycin €2135 (37%, 7%, and 56%), and
other antibiotics €3087 (4%, 10%, and 86%). Extrapolating these costs to an average
German hospital with 300 BSI and 1000 cSSSI patients and increasing daptomycin
use in BSI from 1% to 6% and in cSSSI from 0.3% to 1.4% would save the hospital
€30,151 and €2,971 per year, respectively. CONCLUSIONS: Using daptomycin for
treating cSSSI is budget neutral and using it for bacteremia patients is associated
with favorable economic outcomes when compared with other antibiotics.
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OBJECTIVES: Ceftaroline fosamil (CPT, Teflaro
®
) is a new, broad-spectrum, bacte-
ricidal cephalosporin approved in the United States for the treatment of acute
bacterial skin and skin structure infections (ABSSSI). In two randomized controlled
ABSSSI trials (NCT00424190, NCT00423657), clinical cure rates in the modified in-
tent-to-treat (MITT) population were 85.9%with CPT and 85.5%with vancomycin
aztreonam. Clinical response rates at Day 3 (MITT population, N797) were 74.0%
and 66.2% for CPT and vancomycin  aztreonam combination, respectively. The
objective was to assess the budgetary impact of adding CPT to a hospital formulary
in the United States. METHODS: A three-year hospital budget impact model was
constructed with three initial treatment options; CPT, vancomycin  aztreonam,
and other vancomycin-containing regimens. The target population was hospital-
ized adult, ABSSSI patients. Clinical cure rateswith initial treatmentwere assumed
to be similar to those fromCPT clinical trials. Patients failing initial treatment were
assumed to be treated successfully with a second-line antibiotic therapy. Length of
stay and cost per hospital day (by success or failure with initial treatment) were
estimated based on a large database from over 100 US hospitals. Other model
inputs included: annual number of ABSSSI admissions; projected annual case
growth rate; proportion of ABSSSI target population receiving vancomycin-con-
taining regimen; expected proportion of ABSSSI target population to be treated
with CPT; drug acquisition cost; cost of antibiotic administration; cost of vancomy-
cin monitoring. A sensitivity analysis using 95% confidence limits of clinical cure
rates provided varying estimates. RESULTS: Estimated total cost for treating an
ABSSSI patient with CPT is $313 lower ($13,804 vs. $14,117) than vancomycin 
aztreonam (sensitivity analysis range; $235 to -$833) and $71 lower ($13,804 vs.
$13,875) than other vancomycin-containing regimens (sensitivity analysis range;
$478 to -$1430). CONCLUSIONS: Model estimates indicate adding ceftaroline to
formulary does not negatively impact a hospital ABSSSI budget.
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OBJECTIVES: Assess economic costs of adverse events (AEs) among patients with
human immunodeficiency virus (HIV) treated with non-nucleoside reverse trans-
criptase inhibitors (NNRTIs) including delavirdine, efavirenz, etravirine, and
nevirapine. METHODS: Retrospective cohort study using medical and pharmacy
claims fromUS commercial orMedicare supplemental insurance patients between
January 1, 2004 to September 30, 2009. Adult HIV-patients initiating NNRTI (no
NNRTI use during 6 months prior to first dispensation [index date]) were selected.
AEs included rash, nausea/vomiting, diarrhea, dizziness, headache, sleep-related
symptoms, hepatotoxicity, lipid disorders, depression, anxiety, and self-injury. AE
episode-related care during the year post-initiation was identified by claims asso-
ciated with AE management. AE cases were matched 1:4 to non-AE controls by
propensity of having anAE. “Associated costs” included plan payments and patient
copayments directly related to managing AEs. “Incremental costs” of experiencing
an AE were calculated as the difference in total costs between patients with AE
during the period of each AE episode and non-AE controls (matched period).
RESULTS: The study included 2548 NNRTI users (mean age 43 years; 84%male; 87%
efavirenz; 29% experienced an AE). During 1-year post-index period, annual total
healthcare cost per patient in this study populationwas $27,751 (efavirenz: $26,704;
other NNRTIs: $34,993). Annual mean AE associated costs were $609 per patient
(efavirenz: $555; other NNRTIs: $979). Mean AE associated cost of care (duration)
per AE episode ranged from $586 (88 days) for lipid disorders, $975 (33 days) for
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